Navigation Links
NSAID use associated with lower colorectal cancer mortality rates among postmenopausal women
Date:10/23/2011

BOSTON Postmenopausal women who reported having used nonsteroidal anti-inflammatory drugs for at least 10 years at the time of enrollment in the Women's Health Initiative study had a lower risk for death from colorectal cancer compared with women who reported no use of these drugs at enrollment, according to data presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011.

"Our results suggest that nonsteroidal anti-inflammatory drug (NSAID) use is associated with lower colorectal cancer mortality among postmenopausal women who use these medications more consistently and for longer periods of time," said Anna E. Coghill, M.P.H., a doctoral student in epidemiology at the University of Washington and Fred Hutchinson Cancer Research Center.

She and her colleagues evaluated the association between aspirin and nonaspirin NSAID use and colorectal cancer mortality in 160,143 postmenopausal women enrolled in the Women's Health Initiative (WHI) who did not report a history of colorectal cancer at baseline. The study population included women enrolled in the WHI clinical trials and women enrolled in the WHI observational study.

"The WHI study population represents a large and well-characterized cohort of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use," Coghill said.

Researchers confirmed 2,119 cases of colorectal cancer through medical reports and verified 492 deaths due to colorectal cancer through a centralized medical record and death certificate review.

Coghill and colleagues found that reported use of NSAIDs such as aspirin, ibuprofen and prescription NSAIDs at baseline, by itself, was not associated with colorectal cancer mortality.

However, women in the study who reported using NSAIDs at both study enrollment and three years after study enrollment had an approximately 30 percent lower rate of death due to colorectal cancer compared with women who reported no NASID use or use at only one of these two time points. Researchers also observed significant reductions in colorectal cancer mortality among women who reported at least 10 years of NSAID use at study enrollment compared with those who reported no use.

"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer," Coghill said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. NSAIDs Wont Shield Against Skin Cancer
2. NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs
3. Pitt study finds NSAIDs cause stem cells to self-destruct, preventing colon cancer
4. Long-term NSAID use by hypertensive patients with CAD increases risk of adverse events
5. NSAIDs May Raise Miscarriage Risk: Study
6. NSAID Painkillers Linked to Risk of Kidney Cancer
7. Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use
8. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
9. Certain pain medications do not appear to be associated with skin cancer risk
10. News brief: ALDH associated with worse overall survival in patients with pancreatic adenocarcinoma
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology: